Johnson & Johnson (NYSE:JNJ) is one of the most undervalued NYSE stocks to buy now. On July 8, Johnson & Johnson announced ...

Johnson & Johnson (NYSE:JNJ) submitted a supplemental New Drug Application for CAPLYTA®, aiming to prevent schizophrenia ...

Caplyta is an oral antipsychotic medicine. Here’s how it treats schizophrenia and bipolar depression.

Titusville: Johnson & Johnson has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug ...

Caplyta is a prescription drug used to treat schizophrenia and bipolar depression. Learn about side effects it can cause and how to manage them.

Welcome to Fierce Pharma's regulatory tracker for the second half of 2025. | In this tracker, Fierce Pharma is recording the ...

CAPLYTA ® is the newest addition to Johnson & Johnson's portfolio of schizophrenia therapies, which now offers the broadest range of oral and long-acting injectable treatment options to support ...

Intra-Cellular Therapies develops small-molecule drugs targeting the central nervous system for neuropsychiatric and neurological disorders. Caplyta is their lead drug, approved by the FDA for ...

CAPLYTA is not approved for the treatment of patients with dementia-related psychosis. Contraindications: CAPLYTA is contraindicated in patients with known hypersensitivity to lumateperone or any ...

Caplyta may not be safe to take while pregnant or breastfeeding. Keep reading to learn more about Caplyta and reproductive health. And for a detailed overview of this drug, check out this article.